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Type 1 diabetes (T1D) is an autoimmune disease characterized by the infiltration of lymphocytes into the 
insulin-producing β-cells in the pancreas. We have isolated live T cells sorted or grown directly from the 
isolated, handpicked islets of human donors with T1D. We received ~500 islet equivalent EQ of variable purity 
(10-90%) from 12 donors with T1D (disease duration 0.42-20 years) and from seven control donors and two 
donors with type 2 diabetes (T2D). A total of 321 T cell lines and clones were derived from the islets of donors 
with T1D (3 lines from the 9 control donors). These are 131 CD4+ lines and clones, 47 CD8+ lines and 143 
lines that contain both CD4+ and CD8+ T cells. From 50 lines and clones examined to date, we have 
determined the autoreactivity of 19 and have seen a broad repertoire of T cell autoreactivity in the islets, 
including characterized targets and post-translationally modified targets. Autoreactivity of CD4+ T cell lines 
was to three different peptides from glutamic acid decarboxylase 65 (GAD; GAD115-127, GAD274-286, GAD555-567), 
proinsulin76-90, and to chromogranin A or proinsulin expressed by DR4+DQ8+ B cells transduced with lentivirus 
containing constructs with the open reading frames corresponding to whole autoantigens. Reactivity to 
modified peptides included the glucose-regulated protein 78 and islet amyloid polypeptide with arginine to 
citrulline modifications (GRP78292-305(Arg-Cit297) and IAPP65-84(Arg-Cit 73, 81)), deaminations (IA-2545-562(Gln-Glu 548, 551, 556), 
and to several insulin hybrid peptides. These autoreactive CD4+ T cell lines and clones secreted only pro-
inflammatory cytokines (IFN-γ, TNFα) upon peptide stimulation. For CD8+ T cells from islets, from one donor 
with T1D, we saw binding of a pool of HLA-A2 pentamers loaded with insulin B10-18, IA-2797-805 and insulin 
specific glucose-6-phosphatase catalytic subunit related protein, IGRP265-273. These results have implications 
for the development of successful prevention and reversal therapeutic strategies in T1D. 
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